Predicta Biosciences Raises $5.2M to Improve Myeloma Testing and Monitoring

The emerging precision oncology company Predicta Biosciences has succeeded in raising over $5.2 million from various investors. These funds will be used to expand the company’s team, build a CLIA lab, and improve workflow for bioinformatics and sequencing. 

History of Predicta Biosciences 

Predicta was founded in 2023 by leading multiple myeloma specialists Irene Ghobrial, MD, and Kenneth C. Anderson, MD, with the head of Clinical Research at Mass Gen, Keith Flaherty, MD, and cancer genomic experts Gad Getz, PhD, and Romanos Sklavenitis Pistofidi, MD, PhD. Kate Caves serves as Predicta’s CEO.  

A Reinvention of Myeloma Diagnostics and Monitoring 

Fueled by their passion for making the cancer experience easier on patients and simpler for oncologists, their team’s mission is to improve multiple myeloma (and eventually other blood cancer) diagnostic testing, monitoring, and treatment. 

Kate Caves, the CEO of Predicta, states, “Our mission is twofold: to deliver non-invasive tests that diagnose cancer in the earliest stages, and develop a one-of-a-kind clinical database that identifies new drug targets and immune signatures…[f]or precision medicine to succeed, we need to empower physicians with the tools and knowledge required to make informed decisions and provide the best possible care.”

They’ll achieve these bold goals by integrating cutting-edge multiomics and liquid biopsies to develop innovative products. Curious about multiomics? Multiomics is the study of multiple biological molecules (like DNA, RNA, proteins, and metabolites) in an organism to understand how they work together and influence health and disease.

Their platform utilizes artificial intelligence (AI) and state-of-the-art technology to develop personalized patient treatment options. Predicta is building a diagnostic and monitoring platform that provides targeted information for diagnosis, treatment decisions, and patient monitoring. Patients will be happy to hear that its tests replace painful bone marrow biopsies with simple blood draws.

With these tools, oncologists and other clinicians are empowered to make critical, informed decisions and provide their patients with the best care possible. 

Their platform and products are currently being used in research at Dana Farber Cancer Center in Massachusetts. They plan to launch their diagnostic product, GenoPredicta, commercially early next year.

Conclusion

Myeloma specialist and Predicta cofounder Ken Anderson shares, “[We care] deeply about empowering not only physicians but also patients with detailed information about their unique molecular data, treatment options, and monitoring recommendations.”

He continues, “...Our tests evaluate patients’ immune system cells, equipping physicians with the unique and critical ability to determine the likelihood of a patient responding to new immunotherapies like CAR T-cell therapy and bispecific antibodies.”

Predicta, and companies like it, are drastically improving the myeloma testing and treatment landscape. Research and technology such as this are especially necessary as the cancer treatment landscape grows and patient survival increases, leading physicians to make more cancer-care decisions than ever before. 

​Read more about Predicta’s mission, vision, and products here: Predicta Biosciences 

Sources: 

• Predicta Biosciences
• Predicta Biosciences Secures $5.2M to Transform the Diagnosis, Treatment and Monitoring of Blood Cancers